Morepen Laboratories Limited
NSE: MOREPENLAB BSE: MOREPENLAB
NSE
64.12
-0.35 (-0.54%)
Prev Close
64.47
Open Price
64.75
Volume
2,840,731
Today Low / High
63.5 / 64.89
52 WK Low / High
42 / 100.9
Range
61 - 67
BSE
64.11
-0.32 (-0.50%)
Prev Close
64.43
Open Price
64.57
Volume
129,014
Today Low / High
63.53 / 64.97
52 WK Low / High
41.66 / 100.8
Range
61 - 67
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 64.12 (target range: 61 - 67), reflecting a change of -0.35 (-0.54289%). On the BSE, it is listed at 64.11 (target range: 61 - 67), showing a change of -0.32 (-0.49666%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
05 Jun
64.00
0.73%
04 Jun
64.70
-1.38%
03 Jun
65.02
-0.68%
02 Jun
65.00
-0.22%
30 May
66.35
-2.28%
29 May
65.72
0.76%
28 May
66.88
-2.27%
27 May
66.86
-0.28%
26 May
67.00
-0.57%
23 May
68.14
-2.27%
22 May
65.80
3.13%
21 May
62.90
4.83%
20 May
64.00
-1.83%
19 May
60.65
4.98%
16 May
61.38
-1.32%
15 May
60.50
0.76%
14 May
60.82
-1.22%
13 May
59.26
1.54%
12 May
59.25
1.87%
Morepen Laboratories Limited Graph
Morepen Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Morepen Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 64.12, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 64.11 | 64.75 | 58.28 - 71.23 |
| 65.39 | 52.31 - 78.47 | ||
| 66.03 | 46.22 - 85.84 | ||
| Bearish Scenario | 64.11 | 63.47 | 57.12 - 69.82 |
| 62.83 | 50.26 - 75.39 | ||
| 62.19 | 43.53 - 80.84 |
Overview of Morepen Laboratories Limited
ISIN
INE083A01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
6,902,130
Market Cap
35,326,594,380
Last Dividend
0
Official Website
IPO Date
1996-01-01
DCF Diff
120.68
DCF
-56
Financial Ratios Every Investor Needs
Stock Dividend of MOREPENLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2002-09-18 | September 18, 02 | 0.6 | 0.6 | 2002-09-23 | 2002-10-08 | 2002-07-01 |
| 2001-09-03 | September 03, 01 | 0.2 | 0.2 | 2001-09-16 | 2001-10-01 | 2001-06-16 |
| 2001-01-24 | January 24, 01 | 0.5 | 0.5 | 2001-02-09 | 2001-03-01 | 2001-01-16 |
| 2000-08-18 | August 18, 00 | 0.1 | 0.5 | 2000-09-04 | 2000-10-01 | 2000-07-18 |
| 2000-04-28 | April 28, 00 | 0.6 | 3 | 2000-05-15 | 2000-06-01 | 2000-04-18 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,701.90 Cr | 1,083.52 Cr | 618.38 Cr | 0.3633 | 5.20 Cr | 83.57 Cr | 417.38 Cr | 96.16 Cr | 1.88 | 172.60 Cr | 0.0565 |
| 2023-03-31 | 1,417.53 Cr | 955.74 Cr | 461.79 Cr | 0.3258 | 3.07 Cr | 14.16 Cr | 56.08 Cr | 38.68 Cr | 0.77 | 85.67 Cr | 0.0273 |
| 2022-03-31 | 1,541.57 Cr | 1,060.94 Cr | 480.63 Cr | 0.3118 | 3.01 Cr | 14.19 Cr | 118.01 Cr | 101.68 Cr | 2.26 | 156.77 Cr | 0.0660 |
| 2021-03-31 | 1,175.37 Cr | 786.78 Cr | 388.59 Cr | 0.3306 | 5.65 Cr | 12.17 Cr | 98.17 Cr | 97.09 Cr | 2.16 | 128.45 Cr | 0.0826 |
| 2020-03-31 | 839.60 Cr | 561.95 Cr | 277.65 Cr | 0.3307 | 2.55 Cr | 14.55 Cr | 36.90 Cr | 33.58 Cr | 0.75 | 78.00 Cr | 0.0400 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 16.95 Cr | 1,293.21 Cr | 445.98 Cr | 847.2262 Cr | 29.00 Cr | 12.05 Cr | 248.59 Cr | 301.30 Cr | 1.54 Cr | 0.00 Cr | 0.00 Cr | 402.0446 Cr |
| 2023-03-31 | 21.67 Cr | 1,110.50 Cr | 358.05 Cr | 752.9081 Cr | 25.16 Cr | 3.50 Cr | 228.89 Cr | 184.01 Cr | 66.37 Cr | 34.20 Cr | -33.77 Cr | 321.1631 Cr |
| 2022-03-31 | 15.80 Cr | 1,070.05 Cr | 491.95 Cr | 578.5612 Cr | 18.57 Cr | 2.77 Cr | 275.85 Cr | 160.79 Cr | 180.51 Cr | 33.01 Cr | 0.06 Cr | 456.4569 Cr |
| 2021-03-31 | 41.39 Cr | 858.15 Cr | 433.86 Cr | 424.7498 Cr | 17.05 Cr | -24.34 Cr | 175.33 Cr | 131.24 Cr | 178.15 Cr | 0.00 Cr | 1.09 Cr | 403.8000 Cr |
| 2020-03-31 | 13.64 Cr | 663.46 Cr | 379.87 Cr | 284.0611 Cr | 13.47 Cr | -0.17 Cr | 138.48 Cr | 134.09 Cr | 162.25 Cr | 0.00 Cr | 1.09 Cr | 351.4436 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 73.3746 Cr | -83.3002 Cr | 5.2049 Cr | -7.9609 Cr | -4.7207 Cr | 16.9451 Cr | -71.3808 Cr | 96.1599 Cr | 3.8351 Cr | 0.0000 Cr | -19.7079 Cr |
| 2023-03-31 | -91.1706 Cr | -46.5093 Cr | 143.5431 Cr | -137.1426 Cr | 5.8632 Cr | 21.6658 Cr | -45.9720 Cr | 55.7553 Cr | 6.5951 Cr | 0.0000 Cr | 46.9678 Cr |
| 2022-03-31 | -57.7576 Cr | -31.6785 Cr | 63.8518 Cr | -125.1256 Cr | -25.5843 Cr | 15.8026 Cr | -67.3680 Cr | 126.7026 Cr | 1.5233 Cr | 0.0000 Cr | -100.5287 Cr |
| 2021-03-31 | 50.8257 Cr | -70.3507 Cr | 47.2728 Cr | 10.4273 Cr | 27.7478 Cr | 41.3869 Cr | -40.3984 Cr | 98.5115 Cr | 3.5776 Cr | -0.4892 Cr | -36.8500 Cr |
| 2020-03-31 | 11.0172 Cr | -12.4615 Cr | 5.4883 Cr | -6.0498 Cr | 4.0440 Cr | 13.6391 Cr | -17.0670 Cr | 39.1076 Cr | 1.5242 Cr | -0.4892 Cr | -44.2741 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 452.78 Cr | 290.65 Cr | 162.13 Cr | 0.3581 | 31.21 Cr | 26.69 Cr | 0.49 | 41.48 Cr | 0.0589 |
| 2024-09-30 | 437.73 Cr | 270.10 Cr | 167.63 Cr | 0.3830 | 42.21 Cr | 34.85 Cr | 0.65 | 49.06 Cr | 0.0796 |
| 2024-06-30 | 455.22 Cr | 345.77 Cr | 109.45 Cr | 0.2404 | 15.05 Cr | 36.17 Cr | 0.71 | 55.05 Cr | 0.0795 |
| 2024-03-31 | 360.11 Cr | 255.04 Cr | 105.07 Cr | 0.2918 | 8.58 Cr | 8.24 Cr | 0.17 | 52.62 Cr | 0.0229 |
| 2023-12-31 | 444.55 Cr | 272.04 Cr | 172.51 Cr | 0.3881 | 46.19 Cr | 31.99 Cr | 0.63 | 54.64 Cr | 0.0720 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 19.55 Cr | 184.67 Cr | 204.22 Cr | 0.00 Cr | 282.39 Cr | 1,092.98 Cr | 269.83 Cr | 1,562.25 Cr | 451.82 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 16.95 Cr | 0.00 Cr | 0.00 Cr | 16.95 Cr | 0.00 Cr | 0.00 Cr | -847.23 Cr |
| 2024-03-31 | 52.12 Cr | 49.55 Cr | 52.12 Cr | 324.94 Cr | 248.59 Cr | 889.04 Cr | 237.66 Cr | 1,293.21 Cr | 445.98 Cr |
| 2023-12-31 | -57.84 Cr | 115.69 Cr | 57.84 Cr | 0.00 Cr | 0.00 Cr | 57.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 23.29 Cr | 41.09 Cr | 64.37 Cr | 284.47 Cr | 230.83 Cr | 815.53 Cr | 213.21 Cr | 1,193.78 Cr | 405.25 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 36.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 28.28 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 31.99 Cr | 16.89 Cr | 0.00 Cr | 0.00 Cr | 16.89 Cr | 74.48 Cr | 57.59 Cr | 0.00 Cr | 16.89 Cr |
| 2023-09-30 | 21.26 Cr | 15.37 Cr | 0.00 Cr | 0.00 Cr | 15.37 Cr | 57.59 Cr | 42.22 Cr | 0.00 Cr | 15.37 Cr |
| 2023-06-30 | 14.63 Cr | 15.43 Cr | 0.00 Cr | 0.00 Cr | 15.43 Cr | 38.47 Cr | 23.04 Cr | 0.00 Cr | 15.43 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2000-11-07 | November 07, 00 | 5:1 |
| 1996-09-09 | September 09, 96 | 47:40 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
General Manager of Process Engineering & Technology Transfer
Mr. Bhola Prasad
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Vipul Kumar Srivastava
Gender: male
Year Born: 1985
Head of Medipath Division
Mr. Anubhav Suri
Gender: male
Year Born: 1987
President of International Growth
Mr. Kushal Suri
Gender: male
Year Born: 1989
Chief Operating Officer of API
Ms. Amita Sharma
Gender: female
Year Born: 1966
Functional Head of Talent Acquisition & HRBP
Mr. Vikas Sharma
Gender: male
Year Born:
Manager of Administration
Ms. Sunita Suri
Gender: female
Year Born: 1994
Chairman & MD
Mr. Sushil Suri B.Sc., F.C.A., FCA
Gender: male
Year Born: 1964
Whole-Time Director
Mr. Sanjay Suri
Gender: male
Year Born: 1968
Chief Financial Officer
Mr. Ajay Kumar Sharma
Gender: male
Year Born: 1967
FAQs about Morepen Laboratories Limited
Who is the CEO of the company?
The CEO is Mr. Sushil Suri B.Sc., F.C.A., FCA.
What is the current market price of the stock?
The current price is ₹64.47.
What is the 52-week price range?
The range is ₹42-100.9.
What is the market capitalization of the company?
The market capitalization is ₹3,532.66 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 33.14.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Morepen Laboratories Limited (ISIN: INE083A01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,532.66 crores and an average daily volume of 6,902,130 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.